

Tamara Darsow

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5578455/tamara-darsow-publications-by-year.pdf>

Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

19 papers	1,655 citations	15 h-index	19 g-index
19 ext. papers	1,795 ext. citations	6.2 avg, IF	4.14 L-index

#	Paper	IF	Citations
19	Differentiation of Diabetes by Pathophysiology, Natural History, and Prognosis. <i>Diabetes</i> , 2017 , 66, 241-255	25.5	292
18	Biologic Responses to Weight Loss and Weight Regain: Report From an American Diabetes Association Research Symposium. <i>Diabetes</i> , 2015 , 64, 2299-309	0.9	33
17	The American Diabetes Association diabetes research perspective. <i>Diabetes Care</i> , 2012 , 35, 1380-7	14.6	14
16	Incretin-based therapies. <i>Journal of Diabetes</i> , 2012 , 4, 55-67	3.8	29
15	Efficacy of GLP-1 receptor agonists and DPP-4 inhibitors: meta-analysis and systematic review. <i>Clinical Therapeutics</i> , 2012 , 34, 1247-1258.e22	3.5	200
14	The American Diabetes Association diabetes research perspective. <i>Diabetes</i> , 2012 , 61, 1338-45	0.9	11
13	Pramlintide reduced markers of oxidative stress in the postprandial period in patients with type 2 diabetes. <i>Diabetes/Metabolism Research and Reviews</i> , 2008 , 24, 103-8	7.5	16
12	Pramlintide as an Adjunct to Basal Insulin: Effects on Glycemic Control and Weight in Patients with Type 2 Diabetes Mellitus. <i>Insulin</i> , 2007 , 2, 166-172		2
11	Pramlintide as an adjunct to insulin in patients with type 2 diabetes in a clinical practice setting reduced A1C, postprandial glucose excursions, and weight. <i>Diabetes Technology and Therapeutics</i> , 2007 , 9, 191-9	8.1	30
10	Is the metabolic syndrome a real clinical entity and should it receive drug treatment?. <i>Current Diabetes Reports</i> , 2006 , 6, 357-64	5.6	6
9	Pramlintide in the management of insulin-using patients with type 2 and type 1 diabetes. <i>Vascular Health and Risk Management</i> , 2006 , 2, 203-12	4.4	31
8	Exocytic trafficking is required for nicotine-induced up-regulation of alpha 4 beta 2 nicotinic acetylcholine receptors. <i>Journal of Biological Chemistry</i> , 2005 , 280, 18311-20	5.4	63
7	Vps41p function in the alkaline phosphatase pathway requires homo-oligomerization and interaction with AP-3 through two distinct domains. <i>Molecular Biology of the Cell</i> , 2001 , 12, 37-51	3.5	74
6	Invertase fusion proteins for analysis of protein trafficking in yeast. <i>Methods in Enzymology</i> , 2000 , 327, 95-106	1.7	29
5	Formation of AP-3 transport intermediates requires Vps41 function. <i>Nature Cell Biology</i> , 1999 , 1, 346-53	23.4	108
4	Cytoplasm to vacuole trafficking of aminopeptidase I requires a t-SNARE-Sec1p complex composed of Tlg2p and Vps45p. <i>EMBO Journal</i> , 1999 , 18, 6005-16	13	101
3	Acidic di-leucine motif essential for AP-3-dependent sorting and restriction of the functional specificity of the Vam3p vacuolar t-SNARE. <i>Journal of Cell Biology</i> , 1998 , 142, 913-22	7.3	125

2	Vam7p, a SNAP-25-like molecule, and Vam3p, a syntaxin homolog, function together in yeast vacuolar protein trafficking. <i>Molecular and Cellular Biology</i> , 1998 , 18, 5308-19	4.8	177
1	A multispecificity syntaxin homologue, Vam3p, essential for autophagic and biosynthetic protein transport to the vacuole. <i>Journal of Cell Biology</i> , 1997 , 138, 517-29	7.3	314